Analgesic effect of diprospan in rats with trigeminal neuralgia

Abstract

This study examined the analgesic effect of diprospan in rats with trigeminal neuralgia. Rat model of trigeminal neuralgic pain was established by loosely ligating the left infraorbital branch of the trigeminal nerve. After allodynia developed, the rats were randomly divided into 2 groups (n=20 in each): diprospan group, in which the rats received diprospan (7 mg/mL, 0.1 mL) injected to the left infraorbital foramen area; control group, in which saline (0.1 mL) was administered as the same manner as the diprospan group. The pain threshold (PT) in the left infraorbital area was measured before and 2, 6, and 8 weeks after the administration. The expression of neuropeptides [substance P, preprotachykinin A (PPTA), calcitonin gene-related peptide (CGRP)] in the trigeminal nerve was detected at the same time points as the PT measurement by immunohistochemistry or in situ hybridization method. The results showed that in the diprospan group, the PT was 10.65±1.26, 10.77±1.19 and 14.13±1.34 g 2, 6, and 8 weeks after the administration respectively, significantly higher than that before the administration (PT value: 0.36±0.11) (P<0.05 for each). In the saline group, the PT was 0.37±0.13, 0.66±0.09, 4.45±1.29 and 13.72±1.72 g before and 2, 6, and 8 weeks after the administration respectively with differences being significant between before and 6, 8 weeks after the administration (P<0.01). No significant difference existed in the PT between the diprospan group and the saline group at pre-administration (P>0.05). The PT in the diprospan group was significantly greater than that in the saline group 2 and 6 weeks post-administration (P<0.05). In the diprospan group, the expression levels of neuropeptides were significantly reduced as compared with those in the saline group 2 and 6 weeks post-administration (P<0.05). It was concluded that diprospan has an obvious analgesic effect on the trigeminal neuropathic pain partly by reducing the expression of neuropeptides in the trigeminal ganglia.

Keywords

diprospan / betamethasone / trigeminal neuralgia / pain threshold / substance P / calcitonin gene-related peptide

References

[1] HanS.R., YeoS.P., LeeM.K., et al.. Early dexamethasone relieves trigeminal neuropathic pain. J Dent Res, 2010, 89(9): 915-920

[2] ChinT.H.. Trigeminal neuralgia treated with dexamethasone. Yokohama Med Bull, 1966, 17(4): 115-117

[3] LiangL.M., LiuC.M., HaoG.. Clinical study of treating primary trigeminal neuralgia of aged people by local injection of Diprospan. Chin J Geriatric Dentistry (Chinese), 2007, 5(3): 153-155

[4] WangY.X., TianY.K., GuanS.H., et al.. A clinical study of compound betamethasone injection for treating primary trigeminal neuralgia. J Taishan Medical College (Chinese), 2010, 31(1): 23-25

[5] Idänpään-HeikkiläJ.J., GuilbaudG.. Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behaviour. Pain, 1999, 79(2–3): 281-290

[6] VosB.P., StrassmanA.M., MaciewiczR.J.. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. J Neurosci, 1994, 14(5): 2708-2723

[7] ImamuraY., KawamotoH., NakanishiO.. Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats. Exp Brain Res, 1997, 116(1): 97-103

[8] AndersonL.C., VakoulaA., VeinoteR.. Inflammatory hypersensitivity in a rat model of trigeminal neuropathic pain. Arch Oral Biol, 2003, 48(2): 161-l69

[9] FrommG.H., TerrenceC.F., MaroonJ.C.. Trigeminal neuralgia. Current concepts regarding etiology and pathogenesis. Arch Neurol, 1984, 41(11): 1204-1207

[10] PernowB., SubstanceP.. . Pharmacol Rev, 1983, 35(2): 85-141

[11] AmaraS.G., JonasV., RosenfeldM.G., et al.. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 1982, 298(5871): 240-244

[12] MorrisH.R., PanicoM., EtienneT., et al.. Isolation and characterization of human calcitonin gene-related peptide. Nature, 1984, 308(5961): 746-748

[13] LiX.G., GaoD.A., JinS., et al.. The level of PPTA mRNA and its proteins expression in trigeminal ganglia in rats with occlusal recovery. Shanghai J Stomatology (Chinese), 2008, 17(4): 411-415

[14] LiX.G., YuanL.L., LiuH.J., et al.. Expressions of calcitonin gene-related peptide in rats with occlusal reconstruction. Shanghai J Stomatology, 2006, 15(6): 649-652

[15] StrittmatterM., GrauerM., IsenbergE., et al.. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. Headache, 1997, 37(4): 211-216

[16] GoadsbyP.J., EdvinssonL., EkmanR.. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol, 1988, 23(2): 193-196

[17] BouckomsA.J., PolettiC.H., SweetW.H., et al.. Trigeminal facial pain: a model of peptides and monoamines in intracerebral cerebrospinal fluid. Agressologie, 1991, 32(5): 271-274

[18] MarinkovićS., GiboH., TodorovićV., et al.. Ultrastructure and immunohistochemistry of the trigeminal peripheral myelinated axons in patients with neuralgia. Clin Neurol Neurosurg, 2009, 111(10): 795-800

[19] SeinoH., SeoK., MaedaT., et al.. Behavioural and histological observations of sensory impairment caused by tight ligation of the trigeminal nerve in mice. J Neurosci Methods, 2009, 181(1): 67-72

[20] XuM., AitaM., ChavkinC.. Partial infraorbital nerve ligation as a model of trigeminal nerve injury in the mouse: behavioral, neural, and glial reactions. J Pain, 2008, 9(11): 1036-1048

[21] XieW., LiuX., XuanH., et al.. Effect of betamethasone on neuropathic pain and cerebral expression of NF-kappaB and cytokines. Neurosci Lett, 2006, 393(2–3): 255-259

[22] ZhuangC.Y., CaoP., ZhengT., et al.. Intradiscal interventional therapy for degenerative chronic discogenic low back pain with end-plate Modic changes. Zhonghua Yi Xue Za Zhi (Chinese), 2009, 89(35): 2490-2494